Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial

Diabetes Obes Metab. 2022 Nov;24(11):2273-2276. doi: 10.1111/dom.14809. Epub 2022 Aug 7.
No abstract available

Keywords: GLP-1 analogue; antiobesity drug; clinical trial; obesity therapy; phase III study; weight control.

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides / therapeutic use
  • Humans
  • Hypoglycemic Agents
  • Obesity / complications
  • Obesity / drug therapy
  • Overweight* / complications
  • Overweight* / drug therapy

Substances

  • Hypoglycemic Agents
  • semaglutide
  • Glucagon-Like Peptides

Associated data

  • ClinicalTrials.gov/NCT04074161